What are the 2026 ACC guideline recommendations for initiating and continuing low‑dose aspirin (81 mg) in patients over 70 years, both with and without established atherosclerotic cardiovascular disease (ASCVD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

2026 ACC Guideline Changes on Aspirin for Primary Prevention

There are no 2026 ACC guideline changes specifically addressing aspirin for primary prevention—the most recent comprehensive guidance remains the 2019 ACC/AHA Primary Prevention Guidelines, which recommend against routine aspirin initiation in adults over 70 years for primary prevention (Class III: Harm). 1

Key Recommendations for Patients Over 70 Years

Without Established ASCVD (Primary Prevention)

Aspirin should NOT be routinely initiated in adults over 70 years for primary prevention. 1 The 2019 ACC/AHA guidelines explicitly state that prophylactic aspirin in this age group is "potentially harmful" due to significantly elevated bleeding risk that outweighs any cardiovascular benefit. 1

  • Bleeding risk increases substantially with age, particularly after 60-70 years 2
  • Recent extended follow-up data from the ASPREE trial (2025) reinforces this recommendation, showing no long-term MACE benefit and increased major hemorrhage risk (HR 1.24) in older adults taking aspirin 3
  • The USPSTF (2022) similarly recommends against initiating aspirin in adults ≥60 years (Grade D recommendation) 4

Important caveat: While routine use is not recommended, the guidelines acknowledge "insufficient evidence to comment on whether there may be select circumstances" where aspirin might be discussed with adults >70 years in the context of other high-risk factors (e.g., strong family history of premature MI, inability to achieve risk factor targets, significantly elevated coronary artery calcium). 1 However, this remains a narrow exception requiring careful bleeding risk assessment.

With Established ASCVD (Secondary Prevention)

Aspirin IS recommended for secondary prevention in patients with established ASCVD, regardless of age. 5 This is a fundamentally different indication than primary prevention—the benefit-to-risk ratio strongly favors aspirin use when cardiovascular disease is already present.

For Patients 40-70 Years (Primary Prevention Context)

The 2019 guidelines provide a Class IIb recommendation (may be considered) for aspirin in adults 40-70 years who:

  • Have ≥10% 10-year ASCVD risk
  • Are at low bleeding risk
  • Cannot achieve optimal control of other modifiable risk factors 1

This represents a significant narrowing from previous recommendations, emphasizing that aspirin should be reserved for select higher-risk individuals rather than routine use.

Critical Bleeding Risk Factors to Assess

Avoid aspirin in patients with: 1

  • History of gastrointestinal bleeding or peptic ulcer disease
  • Age >70 years (for primary prevention)
  • Thrombocytopenia or coagulopathy
  • Chronic kidney disease
  • Concurrent use of NSAIDs, steroids, anticoagulants (warfarin, DOACs)

Common Pitfalls

  1. Confusing primary and secondary prevention: Many patients >70 years inappropriately receive aspirin for primary prevention—one registry study found 27.6% of patients were receiving aspirin inappropriately 5

  2. Continuing aspirin initiated years ago: Patients who started aspirin under older guidelines should be reassessed for bleeding risk and whether they truly have established ASCVD

  3. Dose considerations: If aspirin is indicated, use low-dose (81 mg) only—higher doses increase bleeding without additional cardiovascular benefit 1

Note on 2026 Dyslipidemia Guidelines

The 2026 ACC/AHA Dyslipidemia Guidelines 6 focus on cholesterol management and do not modify the 2019 aspirin recommendations for primary prevention. Aspirin guidance remains governed by the 2019 Primary Prevention Guidelines.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.